<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9500169</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20475</journal-id>
<journal-id journal-id-type="nlm-ta">Neurobiol Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurobiol. Dis.</journal-id>
<journal-title-group>
<journal-title>Neurobiology of disease</journal-title>
</journal-title-group>
<issn pub-type="ppub">0969-9961</issn>
<issn pub-type="epub">1095-953X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27189755</article-id>
<article-id pub-id-type="pmc">5108688</article-id>
<article-id pub-id-type="doi">10.1016/j.nbd.2016.05.010</article-id>
<article-id pub-id-type="manuscript">NIHMS789755</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Update of Neurotrophic Factors in Neurobiology of Addiction and Future Directions</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Koskela</surname>
<given-names>Maryna</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bäck</surname>
<given-names>Susanne</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Võikar</surname>
<given-names>Vootele</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Richie</surname>
<given-names>Christopher T.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Domanskyi</surname>
<given-names>Andrii</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harvey</surname>
<given-names>Brandon K.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Airavaara</surname>
<given-names>Mikko</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Institute of Biotechnology, P.O. Box 56, 00014 University of Helsinki, Finland</aff>
<aff id="A2"><label>2</label>Neuroscience Center, P.O. Box 56, 00014, University of Helsinki, Helsinki, Finland</aff>
<aff id="A3"><label>3</label>Intramural Research Program, National Institute on Drug Abuse, NIH, Baltimore, MD, USA</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding author: Mikko Airavaara Ph.D., Institute of Biotechnology, Room 6028B, P.O. Box 56 (Viikinkaari 5D), 00014 University of Helsinki, Finland, Cell: + 358 50 448 0944, <email>mikko.airavaara@helsinki.fi</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>Conflict of interest</bold>
</p>
<p>The authors have no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>24</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>14</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2018</year>
</pub-date>
<volume>97</volume>
<issue>Pt B</issue>
<fpage>189</fpage>
<lpage>200</lpage>
<!--elocation-id from pubmed: 10.1016/j.nbd.2016.05.010-->
<abstract>
<p id="P2">Drug addiction is a chronic brain disease and drugs of abuse cause long lasting neuroadaptations. Addiction is characterized by the loss of control over drug use despite harmful consequences, and high rates of relapse even after long periods of abstinence. Neurotrophic factors (NTFs) are well known for their actions on neuronal survival in the peripheral nervous system. Moreover, NTFs have been shown to be involved in synaptic plasticity in the brain. Brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) are two of the most studied NTFs and both of them have been reported to increase craving when administered into the mesocorticolimbic dopaminergic system after drug self-administration. Here we review recent data on BDNF and GDNF functions in addiction-related behavior and discuss them in relation to previous findings. Finally, we give an insight into how new technologies could aid in further elucidating the role of these factors in drug addiction.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>